Skip to main content

NCI’s Contributions to the Discovery of Selumetinib for Children with NF1

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI’s Contributions to the Discovery of Selumetinib for Children with NF1 was originally published by the National Cancer Institute.”